









Markets
/
Stocks
/
nasdaq-tsha
/

Taysha Gene Therapies Inc

TSHA

4.075USD

-0.245-5.67%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

140.67MMarket Cap

LossP/E TTM



Taysha Gene Therapies Inc

4.075

-0.245-5.67%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Taysha Gene Therapies Inc

Currency: USD Updated: 2026-03-27

Key Insights

Taysha Gene Therapies Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 55 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.36.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Taysha Gene Therapies Inc's Score

Industry at a Glance

Industry Ranking

55 / 391

Overall Ranking

162 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Taysha Gene Therapies Inc Highlights

StrengthsRisks

Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). TSHA-105 is a gene replacement therapy in development for the treatment of SLC13A5 deficiency, a rare autosomal recessive epileptic encephalopathy.

Growing

The company is in a growing phase, with the latest annual income totaling USD 9.77M.

Undervalued

The company’s latest PE is -11.94, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 268.88M shares, decreasing 5.45% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 20.94K shares of this stock.

Analyst Rating

Based on 14 analysts

Buy

Current Rating

11.357

Target Price

+162.90%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Taysha Gene Therapies Inc is 6.45, ranking 245 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 5.49M, representing a year-over-year increase of 171.27%, while its net profit experienced a year-over-year increase of 48.26%.

Score

Industry at a Glance

Previous score

6.46

Change

-0.01



Financials

9.02

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.31

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.25

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Taysha Gene Therapies Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Taysha Gene Therapies Inc is 6.50, ranking 261 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -11.94, which is -142.90% below the recent high of 5.12 and -49.01% above the recent low of -17.79.

Score

Industry at a Glance

Previous score

6.50

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 55/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Taysha Gene Therapies Inc is 8.57, ranking 100 out of 391 in the Biotechnology & Medical Research industry. The average price target is 10.50, with a high of 19.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.57

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 14 analysts

Buy

Current Rating

11.357

Target Price

+179.05%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Taysha Gene Therapies Inc

TSHA

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Taysha Gene Therapies Inc is 6.74, ranking 148 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.55 and the support level at 3.81, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.32

Change

-0.58

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.077

Sell

RSI(14)

39.500

Neutral

STOCH(KDJ)(9,3,3)

16.637

Sell

ATR(14)

0.262

High Vlolatility

CCI(14)

-193.455

Sell

Williams %R

94.161

Oversold

TRIX(12,20)

-0.283

Sell

StochRSI(14)

21.236

Sell

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

4.234

Sell

MA10

4.369

Sell

MA20

4.461

Sell

MA50

4.573

Sell

MA100

4.740

Sell

MA200

4.004

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Taysha Gene Therapies Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 98.16%, representing a quarter-over-quarter increase of 3.20%. The largest institutional shareholder is The Vanguard, holding a total of 13.23M shares, representing 4.61% of shares outstanding, with 32.30% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Manning (Paul B.)

25.60M

+3.02%

RA Capital Management, LP

23.56M

Avoro Capital Advisors LLC

21.70M

Morgan Stanley & Co. LLC

19.08M

+30.12%

BlackRock Institutional Trust Company, N.A.

15.03M

+24.29%

RTW Investments L.P.

24.35M

-2.67%

Vestal Point Capital, LP

5.50M

+83.33%

Fidelity Management & Research Company LLC

14.59M

-6.62%

Goldman Sachs & Company, Inc.

13.20M

+5.40%

The Vanguard Group, Inc.

Star Investors

12.85M

+17.95%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Taysha Gene Therapies Inc is 4.23, ranking 95 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.10. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.